Listed

Collegium Pharmaceutical, Inc

COLLNasdaqCIK 1267565HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$199.9mRevenue, Q2 FY2026, three months to 2026-06-30$199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Aug 6, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$199.9mRevenue, Q2 FY2026, three months to 2026-06-30$199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure+6.3% on a year earlier
  • Gross margin55.2%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $110.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure−2.5 pts on a year earlier
  • Operating margin1.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure−16.8 pts on a year earlier
  • Net margin−7.5%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure−13.9 pts on a year earlier
  • Diluted EPS−$0.46Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figureSign changed from a year earlier
  • Free cash flow$70.8mFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $71.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Capital expenditure: $496.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Report this figure−2.1% on a year earlier

Last eight quarters

Full statements
Revenue$199.9mGross margin 55.2%
Diluted EPS−$0.46, Q2 FY2026
Free cash flow$70.8m, Q2 FY2026
Collegium Pharmaceutical, Inc, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$m159Revenue, Q3 FY2024, three months to 2024-09-30$159.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure182Revenue, Q4 FY2024, three months to 2024-12-31$181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure178Revenue, Q1 FY2025, three months to 2025-03-31$177.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure188Revenue, Q2 FY2025, three months to 2025-06-30$188.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure209Revenue, Q3 FY2025, three months to 2025-09-30$209.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure205Revenue, Q4 FY2025, three months to 2025-12-31$205.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure194Revenue, Q1 FY2026, three months to 2026-03-31$193.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure200Revenue, Q2 FY2026, three months to 2026-06-30$199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure
Gross margin%60.8%Gross margin, Q3 FY2024, three months to 2024-09-30. gross profit / revenueGross profit: $96.8m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $159.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure54.0%Gross margin, Q4 FY2024, three months to 2024-12-31. gross profit / revenueGross profit: $98.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure54.8%Gross margin, Q1 FY2025, three months to 2025-03-31. gross profit / revenueGross profit: $97.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Revenue: $177.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure57.7%Gross margin, Q2 FY2025, three months to 2025-06-30. gross profit / revenueGross profit: $108.4m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $188.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure61.7%Gross margin, Q3 FY2025, three months to 2025-09-30. gross profit / revenueGross profit: $129.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $209.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure62.5%Gross margin, Q4 FY2025, three months to 2025-12-31. gross profit / revenueGross profit: $128.4m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $205.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure60.6%Gross margin, Q1 FY2026, three months to 2026-03-31. gross profit / revenueGross profit: $117.2m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Revenue: $193.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure55.2%Gross margin, Q2 FY2026, three months to 2026-06-30. gross profit / revenueGross profit: $110.3m. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure
Operating margin%21.9%Operating margin, Q3 FY2024, three months to 2024-09-30. operating income / revenueOperating income: $34.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $159.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure20.9%Operating margin, Q4 FY2024, three months to 2024-12-31. operating income / revenueOperating income: $38.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure12.2%Operating margin, Q1 FY2025, three months to 2025-03-31. operating income / revenueOperating income: $21.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Revenue: $177.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure18.7%Operating margin, Q2 FY2025, three months to 2025-06-30. operating income / revenueOperating income: $35.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $188.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure29.7%Operating margin, Q3 FY2025, three months to 2025-09-30. operating income / revenueOperating income: $62.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $209.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure29.6%Operating margin, Q4 FY2025, three months to 2025-12-31. operating income / revenueOperating income: $60.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $205.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure16.0%Operating margin, Q1 FY2026, three months to 2026-03-31. operating income / revenueOperating income: $30.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Revenue: $193.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure1.9%Operating margin, Q2 FY2026, three months to 2026-06-30. operating income / revenueOperating income: $3.7m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure
Net margin%5.9%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $9.3m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $159.3m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure6.9%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $12.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $181.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure1.4%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $2.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $177.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure6.4%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $12.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $188.0m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure15.0%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $31.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $209.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure8.3%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $17.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $205.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure7.5%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $14.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $193.5m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure(7.5%)Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: −$15.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Revenue: $199.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure
Diluted EPS$ per share0.27Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.27 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure0.36Diluted EPS, Q4 FY2024, three months to 2024-12-31$0.36 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure0.07Diluted EPS, Q1 FY2025, three months to 2025-03-31$0.07 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure0.34Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.34 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure0.84Diluted EPS, Q3 FY2025, three months to 2025-09-30$0.84 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure0.46Diluted EPS, Q4 FY2025, three months to 2025-12-31$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure0.40Diluted EPS, Q1 FY2026, three months to 2026-03-31$0.40 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure(0.46)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-06, accession 0001628280-26-053851.Report this figure
Free cash flow$m(9.2)Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: −$9.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107391. Derived: 9-month figure less the 6-month figure.Capital expenditure: $244.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107391. Derived: 9-month figure less the 6-month figure.Report this figure84.1Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $84.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-011992. Derived: 12-month figure less the 9-month figure.Capital expenditure: $570.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-011992. Derived: 12-month figure less the 9-month figure.Report this figure54.6Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $55.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Capital expenditure: $798.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure72.4Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $72.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Capital expenditure: $65.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Report this figure78.3Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $78.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-06, accession 0001104659-25-107391. Derived: 9-month figure less the 6-month figure.Capital expenditure: $188.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-06, accession 0001104659-25-107391. Derived: 9-month figure less the 6-month figure.Report this figure122Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $123.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-011992. Derived: 12-month figure less the 9-month figure.Capital expenditure: $689.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-011992. Derived: 12-month figure less the 9-month figure.Report this figure56.8Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $57.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Capital expenditure: $270.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-07, accession 0001628280-26-031697.Report this figure70.8Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $71.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Capital expenditure: $496.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-06, accession 0001628280-26-053851. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$780.6mGross margin 59.3%
Diluted EPS$1.73, FY2025
Free cash flow$327.6m, FY2025
Collegium Pharmaceutical, Inc, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$m277Revenue, FY2021, twelve months to 2021-12-31$276.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure464Revenue, FY2022, twelve months to 2022-12-31$463.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure567Revenue, FY2023, twelve months to 2023-12-31$566.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure631Revenue, FY2024, twelve months to 2024-12-31$631.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure781Revenue, FY2025, twelve months to 2025-12-31$780.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure
Gross margin%54.4%Gross margin, FY2021, twelve months to 2021-12-31. gross profit / revenueGross profit: $150.6m. XBRL concept us-gaap:GrossProfit. 10-K filed 2024-02-22, accession 0001558370-24-001526.Revenue: $276.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure45.2%Gross margin, FY2022, twelve months to 2022-12-31. gross profit / revenueGross profit: $209.5m. XBRL concept us-gaap:GrossProfit. 10-K filed 2025-02-27, accession 0001558370-25-001801.Revenue: $463.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure57.5%Gross margin, FY2023, twelve months to 2023-12-31. gross profit / revenueGross profit: $326.2m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $566.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure59.8%Gross margin, FY2024, twelve months to 2024-12-31. gross profit / revenueGross profit: $377.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $631.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure59.3%Gross margin, FY2025, twelve months to 2025-12-31. gross profit / revenueGross profit: $463.3m. XBRL concept us-gaap:GrossProfit. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $780.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure
Operating margin%6.4%Operating margin, FY2021, twelve months to 2021-12-31. operating income / revenueOperating income: $17.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2024-02-22, accession 0001558370-24-001526.Revenue: $276.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure7.2%Operating margin, FY2022, twelve months to 2022-12-31. operating income / revenueOperating income: $33.3m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001801.Revenue: $463.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure29.5%Operating margin, FY2023, twelve months to 2023-12-31. operating income / revenueOperating income: $167.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $566.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure26.9%Operating margin, FY2024, twelve months to 2024-12-31. operating income / revenueOperating income: $169.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $631.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure23.0%Operating margin, FY2025, twelve months to 2025-12-31. operating income / revenueOperating income: $179.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $780.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure
Net margin%25.8%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $71.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-22, accession 0001558370-24-001526.Revenue: $276.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure(5.4%)Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: −$25.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-27, accession 0001558370-25-001801.Revenue: $463.9m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure8.5%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $48.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $566.8m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure11.0%Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: $69.2m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $631.4m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure8.1%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $62.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-26, accession 0001628280-26-011992.Revenue: $780.6m. XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure
Diluted EPS$ per share1.86Diluted EPS, FY2021, twelve months to 2021-12-31$1.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure(0.74)Diluted EPS, FY2022, twelve months to 2022-12-31−$0.74 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure1.29Diluted EPS, FY2023, twelve months to 2023-12-31$1.29 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure1.86Diluted EPS, FY2024, twelve months to 2024-12-31$1.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure1.73Diluted EPS, FY2025, twelve months to 2025-12-31$1.73 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure
Free cash flow$m102Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $103.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-22, accession 0001558370-24-001526.Capital expenditure: $1.9m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-22, accession 0001558370-24-001526.Report this figure123Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $124.2m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-27, accession 0001558370-25-001801.Capital expenditure: $1.6m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-27, accession 0001558370-25-001801.Report this figure274Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $274.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-011992.Capital expenditure: $461.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure203Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $205.0m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-011992.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure328Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $329.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-26, accession 0001628280-26-011992.Capital expenditure: $1.7m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-26, accession 0001628280-26-011992.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Collegium Pharmaceutical, Inc
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$197.0m5,441,202Added+307,175
Jupiter Topco LLC2026-06-30$77.7m2,147,072Not compared
Invesco Ltd.2026-06-30$68.1m1,882,499Added+290,590
JANUS HENDERSON GROUP PLC2026-03-31$60.4m1,825,651Not compared
FULLER & THALER ASSET MANAGEMENT, INC.2026-06-30$59.1m1,632,781Added+133,197
PRINCIPAL FINANCIAL GROUP INC2026-06-30$59.1m1,632,360Added+337,332
STATE STREET CORP2026-06-30$55.3m1,528,881Added+104,337
MASSACHUSETTS FINANCIAL SERVICES CO /MA/2026-06-30$50.9m1,405,567Added+39,635
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$50.0m1,381,261Added+47,269
RENAISSANCE TECHNOLOGIES LLC2026-06-30$49.5m1,366,549Reduced−102,900

Recent filings

All 852 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Collegium Pharmaceutical, Inc, recent filings
FiledFormWhat it isAccession number
2026-10-1916:05 ET8-K1.02 Termination of a material agreement0001104659-26-116876
2026-08-1307:30 ET8-K8.01 Other events0001104659-26-095464
2026-08-0607:34 ET10-QQuarterly reportPeriod 2026-06-300001628280-26-053851
2026-08-0607:33 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure0001628280-26-053849
2026-06-3016:05 ET8-K/A9.01 Financial statements and exhibits0001104659-26-079323
2026-05-1516:10 ET8-K5.07 Shareholder vote results0001104659-26-062536
2026-05-1207:43 ET8-K2.01 Completion of an acquisition or disposition; 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001104659-26-059018
2026-05-0707:34 ET10-QQuarterly reportPeriod 2026-03-310001628280-26-031697
2026-05-0707:33 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001628280-26-031694
2026-04-0716:02 ETDEF 14AProxy statementPeriod 2026-05-140001628280-26-024063

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 26, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by [object Promise].Forecast this quarter

About the filer

CIK
1267565
Tickers
COLL
Exchange
Nasdaq
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
VA
Filer category
Large accelerated filer
Former names
COLLEGIUM PHARMACEUTICAL INC (to 2015-03-03)

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 10:36 ET. Listed shows no prices and gives no investment advice.